## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -2.5% below STRENGTH zone (3.0-6.0%); PEG 3.05 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Colgate-Palmolive Company (NYSE:CL) is a favorite amongst institutional investors who own 86%**
- Source: Simply Wall Street | 20260104T143646 | Somewhat-Bullish | Relevance: 100%
- Institutional investors own 86% of Colgate-Palmolive Company (NYSE:CL), indicating that their trading actions significantly influence the stock price. The top 24 shareholders collectively hold 50% of the business, suggesting broad ownership among institutions rather than concentrated control, with the largest single shareholder being The Vanguard Group, Inc. at 10%. Insider ownership is less than 1%, but their combined holdings are valued at US$70 million, while the general public holds a 14% stake.

**2. Colgate-Palmolive Company (NYSE:CL) is a favorite amongst institutional investors who own 86%**
- Source: Simply Wall Street | 20260104T140745 | Somewhat-Bullish | Relevance: 100%
- Institutional investors own 86% of Colgate-Palmolive Company (NYSE:CL), indicating their strong interest and potential influence on the stock price. The Vanguard Group is the largest shareholder with 10%, and the top 24 shareholders collectively own 50% of the company. Individual investors hold a smaller, but still significant, portion at 14%, while insiders own less than 1%.

**3. Colgate-Palmolive Stock Brushes Up Against Its Highs: Defensive Darling Or Overpolished Trade?**
- Source: AD HOC NEWS | 20260103T021617 | Bullish | Relevance: 100%
- Colgate-Palmolive's stock is trading near its 52-week high after a strong three-month run, driven by new innovations, cost initiatives, and investor confidence in its defensive qualities. Wall Street analysts are largely positive, with recommendations leaning towards Buy or Overweight, although some express caution about valuation. The company's future performance hinges on sustaining volume growth, managing input costs, and continuing to refresh its product lineup.

**4. Colgate Palmolive India Sees ₹61.25 Crore NSE Block Trade at ₹2,091.20 Per Share**
- Source: scanx.trade | 20260105T100754 | Neutral | Relevance: 100%
- Colgate Palmolive India (COLPAL) witnessed a significant block trade on the NSE valued at ₹61.25 crores, involving approximately 292,883 shares at ₹2,091.20 each. This institutional transaction indicates substantial investor activity and portfolio adjustments within the consumer goods sector. The article also mentions a separate block trade of ₹22.49 crores at ₹2,093.00 per share and details how such trades reflect institutional sentiment and liquidity for the company.

**5. Colgate announces major change impacting all of its toothpaste products: 'Addresses a longstanding ... challenge'**
- Source: The Cool Down | 20260104T173145 | Bullish | Relevance: 100%
- Colgate-Palmolive has announced that its toothpaste tubes made in Brazil are now fully recyclable, marking a significant step towards sustainable packaging. The company developed a new tube design using high-density polyethylene, which can be recycled using existing methods, and has made this technology open-source to encourage broader industry adoption. This initiative aims to reduce plastic pollution and microplastics, addressing a long-standing challenge in the personal care sector.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $88 | $87 | +1% |
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.2% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.1x requires aggressive growth execution.
3. Long-term trend broken: trading 9.6% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.05 signals overvaluation risk, limited margin of safety. Forward P/E 20.0x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.2B |
| Beta | 0.30 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.05 |
| Forward P/E | 20.0 |
| Current P/E | 21.0 |
| YoY Growth | 5.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.3% to -2.5% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 41. OFD pattern: +DLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.51% (CS: 12) | Weak |
| RSI_14 | 40.9 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 0.981x | Below |
| vs SMA200 | 0.904x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.93
- **Stop Loss:** $74.43 (3.2% risk)
- **Target:** $79.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 230
- **Position Value:** $17,693.90
- **Portfolio %:** 17.69%
- **Risk Dollars:** $575.00
- **Risk Per Trade:** 0.57%
- **Modifiers:** L1 115% | L2 50% | Combined 0.57x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*